---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-23-000105"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-07T23:52:12.139056+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Exagen amends ATM facility with I.B.6 float limitation; $50M capacity unchanged

## Summary
- Amendment adds General Instruction I.B.6 limit: sales capped at one-third of public float per any 12-month period while float below $75M.
- Total at-the-market equity offering capacity remains at up to $50 million.
- No shares have been sold under I.B.6 in the prior 12-month period ending Nov 17, 2023.
- Amendment dated November 17, 2023, with TD Cowen (formerly Cowen and Company, LLC).

## SEC filing metadata
- accession: 0001274737-23-000105
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000105/0001274737-23-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000105/exdx-20231117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-23-000105
- JSON: https://secwatch.observer/filing/0001274737-23-000105.json
- Plain text: https://secwatch.observer/filing/0001274737-23-000105.txt

## Key facts
- Material Agreements
  EXAGEN INC. amended Amendment No. 1 to the Sales Agreement with Cowen and Company, LLC valued at up to $50,000,000 (effective 2023-11-17).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: up to $50,000,000
  - Effective: 2023-11-17
  source text: On November 17, 2023, Exagen Inc. (the “Company”) entered into Amendment No. 1 (“Amendment No. 1”) to that certain sales agreement, dated September 15, 2022 (the “Sales Agreement”), by and between the Company and Cowen and Company, LLC (“TD Cowen”) in connection with the continuation of the Company’s at-the-market equity offering program (the “Program”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000105/0001274737-23-000105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.